QuidelOrtho (QDEL) AI Stock Analysis

• Market Cap: $1.80B
• Dividend Yield: N/A
• Average Volume (3M): 1.55M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.19
• Revenue Growth: -3.43%
• EPS Growth: 38.98%
• Country: US
• Employees: 6,600
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.80
• Shares Outstanding: 67,931,540
• 10 Day Avg. Volume: 1,132,926
• 30 Day Avg. Volume: 1,549,745
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.99
• Price to Sales (P/S): 1.06
• P/FCF Ratio: -26.38
• Enterprise Value/Market Cap: 2.59
• Enterprise Value/Revenue: 1.72
• Enterprise Value/Gross Profit: 3.01
• Enterprise Value/Ebitda: -9.02
• 1Y Price Target: $27.75
• Price Target Upside: 4.60% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 6
• EPS Forecast (FY): 2.12
• Revenue Forecast (FY): $2.71B

• Rating: 50 Neutral
• Price Target: $28.00 ▲(5.54% Upside)

QuidelOrtho's overall stock score reflects significant financial challenges, including declining revenue and profitability, and negative cash flow. While the earnings call showed some positive aspects like organic sales growth and cost savings, the negative valuation metrics and technical indicators suggest caution. The company's efforts to improve EBITDA margins and regional growth are positive, but the financial instability remains a major concern.

Positive Factors

Organic Sales Growth

The 5% organic sales growth indicates resilience and strength in QuidelOrtho's diversified diagnostics portfolio, supporting long-term revenue stability.

Cost Savings and Margin Improvement

Significant cost savings and margin improvements enhance profitability, providing a solid foundation for sustainable financial performance.

Strong Regional Performance

Strong regional growth, particularly in Latin America, highlights QuidelOrtho's successful market expansion and potential for future revenue increases.

Negative Factors

Decline in COVID and Donor Screening Revenue

The decline in COVID and donor screening revenue presents a challenge, impacting overall revenue and necessitating diversification to offset losses.

Negative Adjusted Free Cash Flow

Negative free cash flow indicates liquidity issues, potentially limiting QuidelOrtho's ability to invest in growth and manage operations efficiently.

Goodwill Impairment Charge

The significant goodwill impairment reflects past overvaluation of assets, impacting financial statements and investor confidence in asset quality.

QuidelOrtho Business Overview & Revenue Model

Company Description

QuidelOrtho Corporation is a leading provider of diagnostic solutions, specializing in medical devices and innovative technologies that enhance patient care. The company operates primarily in the infectious disease, women's health, and respiratory sectors, offering a range of products that include rapid diagnostic tests, assays, and molecular diagnostic systems. QuidelOrtho's core mission is to empower healthcare providers with tools that facilitate timely and accurate diagnoses, thereby improving patient outcomes across various healthcare settings.

How the Company Makes Money

QuidelOrtho generates revenue through multiple key streams, primarily from the sale of its diagnostic products, including rapid tests and laboratory systems. The company's revenue model is built on a combination of direct product sales, recurring revenue from test kits and assays, and partnerships with healthcare providers and distributors. QuidelOrtho also benefits from long-term contracts with hospitals and clinics, which provide a stable income base. Collaborations with research institutions and healthcare organizations further enhance its earnings potential, enabling the development of novel diagnostic solutions and expanding its market reach. Additionally, government contracts, particularly during public health emergencies, can significantly boost revenue through increased demand for diagnostic testing.

QuidelOrtho Financial Statement Overview

Summary

QuidelOrtho is experiencing financial difficulties, with declining revenue, profitability, and cash flow. The company faces significant challenges in reversing these trends, as evidenced by negative margins and cash flow metrics. While the balance sheet shows moderate leverage, the negative return on equity and cash flow issues pose risks to financial stability.

Income Statement

QuidelOrtho's income statement shows significant challenges with declining revenue and profitability. The TTM data reveals a negative net profit margin of -43.43% and a gross profit margin of 57.07%. The company has faced a substantial revenue decline of 99.2% in the TTM period. Historical data shows a consistent decline in revenue growth and profitability margins, indicating financial instability.

Balance Sheet

The balance sheet reflects a moderate financial position with a debt-to-equity ratio of 0.16 in the TTM period, indicating manageable leverage. However, the return on equity is negative, at -43.64%, suggesting inefficiencies in generating returns from equity. The equity ratio is not explicitly calculated but appears stable given the total assets and equity figures.

Cash Flow

Cash flow analysis indicates significant challenges, with a negative free cash flow growth rate of -134.71% in the TTM period. The operating cash flow to net income ratio is low at 0.048, and the free cash flow to net income ratio is negative, highlighting cash flow constraints and potential liquidity issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.72B	2.78B	3.00B	3.27B	1.70B	1.66B
Gross Profit	1.55B	1.29B	1.49B	1.94B	1.28B	1.35B
EBITDA	-518.20M	-1.49B	607.00M	1.09B	953.30M	1.10B
Net Income	-1.18B	-2.05B	-10.10M	548.70M	704.20M	810.29M
Balance Sheet
Total Assets	5.68B	6.42B	8.56B	8.86B	2.43B	1.87B
Cash, Cash Equivalents and Short-Term Investments	98.10M	98.30M	167.30M	345.00M	828.50M	489.94M
Total Debt	2.84B	2.68B	2.61B	2.85B	139.30M	108.50M
Total Liabilities	3.64B	3.44B	3.56B	3.92B	501.00M	538.46M
Stockholders Equity	2.04B	2.98B	5.01B	4.93B	1.93B	1.33B
Cash Flow
Free Cash Flow	-42.80M	-112.10M	70.90M	744.40M	513.14M	564.84M
Operating Cash Flow	37.00M	83.00M	280.20M	885.30M	805.87M	629.76M
Investing Cash Flow	-181.00M	-149.90M	-187.60M	-1.64B	-319.53M	-63.32M
Financing Cash Flow	98.00M	48.80M	-265.80M	252.00M	-173.18M	-130.28M

QuidelOrtho Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 26.53
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QDEL, the sentiment is Positive. The current price of 26.53 is above the 20-day moving average (MA) of 23.79, below the 50-day MA of 26.56, and below the 200-day MA of 29.35, indicating a neutral trend. The MACD of 0.29 indicates Negative momentum. The RSI at 58.49 is Neutral, neither overbought nor oversold. The STOCH value of 80.23 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for QDEL.

QuidelOrtho Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HAE	70 Outperform	$3.79B	23.62	19.47%	―	-2.45%	41.50%
HOLX	69 Neutral	$16.68B	30.13	11.12%	―	1.74%	-25.29%
MASI	56 Neutral	$8.12B	―	-17.93%	―	-16.03%	-813.48%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
QDEL	50 Neutral	$1.80B	―	-44.21%	―	-3.43%	38.98%
STAA	49 Neutral	$1.29B	―	-24.65%	―	-32.42%	-540.37%
BAX	40 Neutral	$9.68B	―	-4.70%	2.76%	-21.20%	-325.40%

QuidelOrtho Corporate Events

QuidelOrtho Reports Strong Q3 2025 Financial Results

QuidelOrtho Corporation reported its third-quarter 2025 financial results, highlighting significant improvements in operational performance and cost savings of over $140 million since early 2024. The company achieved a 180 basis point increase in adjusted EBITDA margin to 25% and a 7% reduction in non-GAAP operating expenses year-over-year. Revenue for the quarter reached $700 million, with a 5% growth excluding COVID-19 and Donor Screening. The company also announced the FDA clearance of its VITROS High Sensitivity Troponin assay, enhancing its cardiac testing capabilities. Additionally, QuidelOrtho completed debt refinancing to improve financial flexibility and continued its site consolidation plan, expecting $20 million in annual savings. Despite macroeconomic pressures, the company remains on track to achieve its 2025 financial goals, with a strong outlook for profitability and growth.

The most recent analyst rating on (QDEL) stock is a Hold with a $23.00 price target. To see the full list of analyst forecasts on QuidelOrtho stock, see the QDEL Stock Forecast page.

QuidelOrtho’s Strategic Growth Amidst Challenges

QuidelOrtho Corporation’s recent earnings call painted a picture of resilience and strategic growth amidst a challenging landscape. The company demonstrated robust performance in organic sales growth and cost savings, despite facing headwinds from declining COVID and donor screening revenues, negative cash flow due to system conversion, and a substantial goodwill impairment charge.

QuidelOrtho Corporation Reports Q3 2025 Financial Results

QuidelOrtho Corporation, a leader in in vitro diagnostics, provides diagnostic solutions across clinical chemistry, immunoassay, immunohematology, and molecular testing sectors, aiming to improve patient outcomes through innovative technology.

QuidelOrtho Completes Major Debt Refinancing Transaction

On August 21, 2025, QuidelOrtho Corporation completed a significant debt refinancing transaction, entering into a Credit Agreement with Bank of America and other lenders. This agreement includes a $1.15 billion senior secured term loan A, a $100 million delayed draw term loan A, a $1.45 billion senior secured term loan B, and a $700 million revolving credit facility. The refinancing allows QuidelOrtho to extend its debt maturities, reduce required amortization payments, and improve financial flexibility, supporting future growth and strengthening its capital structure.

The most recent analyst rating on (QDEL) stock is a Hold with a $26.00 price target. To see the full list of analyst forecasts on QuidelOrtho stock, see the QDEL Stock Forecast page.